ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release' technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release' platform drives value through better products delivered with greater efficiency. In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing. For more information on our services and Lock Release please visit www.adcbio.com